Selected article for: "gold standard and isothermal amplification"
Author: Daniel J Butler; Christopher Mozsary; Cem Meydan; David C Danko; Jonathan Foox; Joel Rosiene; Alon Shaiber; Ebrahim Afshinnekoo; Matthew MacKay; Fritz J Sedlazeck; Nikolay A Ivanov; Maria A Sierra; Diana Pohle; Michael Zeitz; Vijendra Ramlall; Undina Gisladottir; Craig D Westover; Krista Ryon; Benjamin Young; Chandrima Bhattacharya; Phyllis Ruggiero; Bradley W Langhorst; Nathan A Tanner; Justyn Gawrys; Dmitry Meleshko; Dong Xu; Jenny Xiang; Angelika Iftner; Daniela Bezdan; John Sipley; Lin Cong; Arryn Craney; Priya Velu; Ari Melnick; Iman A Hajirasouliha; Thomas Iftner; Mirella Salvatore; Massimo Loda; Lars F Westblade; Shawn Levy; Melissa Cushing; Nicholas P Tatonetti; Marcin Imielinski; Hanna Rennert; Christopher Mason
Title: Host, Viral, and Environmental Transcriptome Profiles of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
  • Document date: 2020_4_20
    • ID: kyoa5gsf_2
    Snippet: The presenting symptoms of COVID-19 resemble those of common viral respiratory infections. As a result, molecular diagnosis is required to reliably distinguish SARS-CoV-2 infection from influenza and the agents of the common cold (Guan et al., 2020 , Zhou et al., 2020 . Current approaches to molecular testing are mostly limited to hospital laboratories and are largely reserved for the most severe cases, with limited accessibility to the general p.....
    Document: The presenting symptoms of COVID-19 resemble those of common viral respiratory infections. As a result, molecular diagnosis is required to reliably distinguish SARS-CoV-2 infection from influenza and the agents of the common cold (Guan et al., 2020 , Zhou et al., 2020 . Current approaches to molecular testing are mostly limited to hospital laboratories and are largely reserved for the most severe cases, with limited accessibility to the general population. As a result, the prevalence of SARS-CoV-2 in the population is mostly unknown, particularly among mild or asymptomatic cases. Though several novel, scalable biotechnological innovations for viral testing have recently emerged (e.g., CRISPR-Cas12a (Broughton et al., 2020) or CRISPR-Cas13 (Metsky et al., 2020) on paper-based detection systems, or loop-mediated isothermal amplification (LAMP) (Tanner et al., 2015 , Schmid-Burgk et. al., 2020 these have not been validated against gold-standard clinical assays or nextgeneration sequencing (NGS).

    Search related documents:
    Co phrase search for related documents
    • clinical assay and detection system: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
    • clinical assay and general population: 1, 2, 3
    • clinical assay and gold standard clinical assay: 1, 2
    • clinical assay and hospital laboratory: 1, 2, 3, 4
    • clinical assay and isothermal amplification: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • clinical assay and molecular diagnosis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • clinical assay and molecular testing: 1, 2, 3, 4, 5, 6, 7, 8
    • common cold and current approach: 1
    • common cold and detection system: 1
    • common cold and general population: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • common cold and hospital laboratory: 1
    • common cold and molecular diagnosis: 1, 2
    • common cold and molecular testing: 1, 2, 3
    • common viral respiratory infection and general population: 1
    • current approach and detection system: 1, 2, 3
    • current approach and general population: 1, 2, 3, 4, 5, 6
    • current approach and isothermal amplification: 1, 2
    • current approach and molecular testing: 1, 2
    • detection system and molecular testing: 1, 2, 3, 4